Skip to main content
SpringerLink
Log in
Book cover

Cured II ■ LENT Cancer Survivorship Research and Education pp 155–162Cite as

Risk Factors for Second Malignancies Following Stem Cell Transplant

  • Chapter

  • 514 Accesses

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

Abstract

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for numerous malignancies, as well as immunologic, hematologic and metabolic disorders. While many patients are cured of their primary disease, a proportion develops posttransplant (secondary) malignant neoplasms (SMN) [2, 19, 29]. Individuals treated with HCT may have been exposed to pre-transplant chemotherapy or radiotherapy, then to additional cytotoxic therapy as part of the preparative regimen for transplantation, and eventually, to immune suppression. All of these factors may act alone or in concert to increase the risk for SMNs. Patients may also be innately cancer susceptible and have a genetic predisposition towards multiple primary malignancies. Potential risk factors for SMN following hematopoietic stem cell transplantation are listed in Tables 14.1 and 14.2.

General risk factors for post-transplant malignancies

Post-transplant SMN specific risk factors

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andre M, Henry-Amar M, Blaise D et al (1998) Treatmentrelated deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood 92:1933–1940

    CAS  PubMed  Google Scholar 

  2. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL (2003) New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 21:1352–1358

    Article  PubMed  Google Scholar 

  3. Baria K, Warren C, Roberts SA, West CM, Scott D (2001) Chromosomal radiosensitivity as a marker of predisposition to common cancers. Br J Cancer 84:892–896

    Article  CAS  PubMed  Google Scholar 

  4. Baria K, Warren C, Eden OB, Roberts SA, West CM, Scott D (2002) Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. Int J Radiat Biol 78:341–346

    Article  CAS  PubMed  Google Scholar 

  5. Bennett LM (1999) Breast cancer: genetic predisposition and exposure to radiation. Molecular Carcinogenesis 26:143–149

    Article  CAS  PubMed  Google Scholar 

  6. Berwick M, Song Y, Jordan R, Brady MS, Orlow I (2001) Mutagen sensitivity as an indicator of soft tissue sarcoma risk. Environ Mol Mutagen 38:223–226

    Article  CAS  PubMed  Google Scholar 

  7. Bhatia S, Ramsay NK, Steinbuch M et al (1996) Malignant neoplasms following bone marrow transplantation. Blood 87:3633–3639

    CAS  PubMed  Google Scholar 

  8. Bhatia S, Louie AD, Bhatia R et al (2001) Solid cancers after bone marrow transplantation. J Clin Oncol 19:464–471

    CAS  PubMed  Google Scholar 

  9. Bondy ML, Wang LE, El-Zein R, de Andrade M, Selvan MS, Bruner JM, Levin VA, Alfred Yung WK, Adatto P, Wei Q (2001) Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst 93:1553–1557

    CAS  PubMed  Google Scholar 

  10. Buchholz TA, Wu X (2001) Radiation-induced chromatid breaks as a predictor of breast cancer risk. Int J Radiat Oncol Biol Phys 49:533–537

    Article  CAS  PubMed  Google Scholar 

  11. Curtis RE, Rowlings PA, Deeg HJ et al (1997) Solid cancers after bone marrow transplantation New Engl J Med 336:897–904

    Article  CAS  PubMed  Google Scholar 

  12. Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME, Travis WD, Travis LB, Horowitz MM, Deeg HJ (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105:3802–3811

    Article  CAS  PubMed  Google Scholar 

  13. Deeg HJ, Witherspoon RP (1993) Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 7:417–429

    CAS  PubMed  Google Scholar 

  14. Deeg HJ, Socie G (1998) Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 91:1833–1844

    CAS  PubMed  Google Scholar 

  15. Deeg HJ, Socie G, Schoch G et al (1996) Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87:386–392

    CAS  PubMed  Google Scholar 

  16. Deeg HJ, Leisenring W, Storb R et al (1998) Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 91:3637–3645

    CAS  PubMed  Google Scholar 

  17. Deeg HJ, Schwartz JL, Friedman D, Leisenring W (2003) Secondary malignancies after hemopoietic stem cell transplantation. Turk J Med Sci 33:207–214

    Google Scholar 

  18. Epstein E Jr (2001) Genetic determinants of basal cell carcinoma risk. Med Pediatr Oncol 36:555–558

    Article  PubMed  Google Scholar 

  19. Friedman DL, Leisenring W, Schwartz JL, Deeg HJ (2004) Second malignant neoplasms following hematopoietic stem cell transplantation. Int J Hematol 79:229–234

    Article  PubMed  Google Scholar 

  20. Friedman DL, Leisenring W, Flowers MED, Holmberg L, Schwartz J, Deeg HJ (2004) Risk factors for second malignancies after transplantation differ between allogeneic and autologous recipients. Presented at the American Society of Hematology Annual Meeting 2004

    Google Scholar 

  21. Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers MED, Tichelli A, Sanders JE, Deeg HJ, Socie G (2008) Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 111:939–944

    Article  CAS  PubMed  Google Scholar 

  22. Gallagher G, Forrest DL (2007) Second solid cancers after allogeneic stem cell transplantation. Cancer 109:84–92

    Article  PubMed  Google Scholar 

  23. Hannan MA, Siddiqui Y, Rostom A, Al-Ahdal MN, Chaudhary MA, Kunhi M (2001) Evidence of DNA repair/processing defects in cultured skin fibroblasts from breast cancer patients. Cancer Research 61:3627–3631

    CAS  PubMed  Google Scholar 

  24. Hosing C, Munsell M, Yazji S et al (2002) Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 13:450–459

    Article  CAS  PubMed  Google Scholar 

  25. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc of the Natl Acad Sci USA 68:820–823

    Article  Google Scholar 

  26. Krishnan A, Bhatia S, Slovak ML et al (2000) Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95:1588–1593

    CAS  PubMed  Google Scholar 

  27. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24:1119–1126

    Article  PubMed  Google Scholar 

  28. Li FP, Fraumeni JF Jr (1969) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43:1365–1373

    CAS  PubMed  Google Scholar 

  29. Lowe T, Bhatia S, Somlo G (2007) Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 13:1121–1134

    Article  PubMed  Google Scholar 

  30. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309–1315

    Article  CAS  PubMed  Google Scholar 

  31. Metayer C, Curtis RE, Vose J et al (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101:2015–2023

    Article  CAS  PubMed  Google Scholar 

  32. Milligan DW (2000) Secondary leukaemia and myelodysplasia after autografting for lymphoma: is the transplant to blame? Leuk Lymphoma 39:223–228

    CAS  PubMed  Google Scholar 

  33. Mossman KL (1997) Radiation protection of radiosensitive populations. Health Physics 72:519–523

    Article  CAS  PubMed  Google Scholar 

  34. Papworth R, Slevin N, Roberts SA, Scott D (2001) Sensitivity to radiation-induced chromosome damage may be a marker of genetic predisposition in young head and neck cancer patients. Br J Cancer 84:776–782

    Article  CAS  PubMed  Google Scholar 

  35. Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273–3279

    CAS  PubMed  Google Scholar 

  36. Potter JD (2002) At the interfaces of epidemiology, genetics, and genomics. Nat Rev Genet 2:142–147

    Article  Google Scholar 

  37. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D (1999) Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer. Am J Hum Genet 65:784–794

    Article  CAS  PubMed  Google Scholar 

  38. Rowlings PA, Curtis RE, Passweg JR et al (1999) Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol 17:3122–3127

    CAS  PubMed  Google Scholar 

  39. Scott D (2000) Chromosomal radiosensitivity, cancer predisposition and response to radiotherapy. Strahlenther Onkol 176:229–234

    Article  CAS  PubMed  Google Scholar 

  40. Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278:1262–1267

    Article  PubMed  Google Scholar 

  41. Socie G, Curtis RE, Deeg HJ et al (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18:348–357

    CAS  PubMed  Google Scholar 

  42. Strong LC, Williams WR, Tainsky MA (1992) The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 135:190–199

    CAS  PubMed  Google Scholar 

  43. Varley JM, Evans DG, Birch JM (1997) Li-Fraumeni syndrome — a molecular and clinical review. Br J Cancer 76:1–14

    CAS  PubMed  Google Scholar 

  44. West CM, Hendry JH (1992) Intrinsic radiosensitivity as a predictor of patient response to radiotherapy. BJR Suppl 24:146–152

    CAS  PubMed  Google Scholar 

  45. Wong FL, Boice JD Jr, Abramson DH et al (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278:1262–1267

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt-Ingram Cancer Center, 2525 West End Avenue, Sixth Flooor, Nashville, TN, 37203, USA

    Debra L. Friedman MD

Authors
  1. Debra L. Friedman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA

    Philip Rubin MD (Professor Emeritus, Chair Emeritus) & Paul Okunieff MD (Philip Rubin Professor of Radiation Oncology, Chair) (Professor Emeritus, Chair Emeritus) &  (Philip Rubin Professor of Radiation Oncology, Chair)

  2. Department of Radiation Oncology James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 704, Rochester, NY, 14642, USA

    Louis S. Constine MD (Professor of Radiation Oncology and Pediatrics, Vice Chair) (Professor of Radiation Oncology and Pediatrics, Vice Chair)

  3. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Campus Box 7512, Chapel Hill, NC, 27599, USA

    Lawrence B. Marks MD (Professor and Chair) (Professor and Chair)

  4. Duke University Medical Center, P.O. Box 3085, Durham, NC, 27710, USA

    Lawrence B. Marks MD (Professor and Chair) (Professor and Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Friedman, D.L. (2008). Risk Factors for Second Malignancies Following Stem Cell Transplant. In: Rubin, P., Constine, L.S., Marks, L.B., Okunieff, P. (eds) Cured II ■ LENT Cancer Survivorship Research and Education. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-76271-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-76271-3_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-76270-6

  • Online ISBN: 978-3-540-76271-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation